Zheng Qinghua, Li Jianfeng, Yang Lijuan
The Third Pediatric Ward, Dongying City People's Hospital, Dongying, 257000, China.
The Third Pediatric Ward, Dongying City People's Hospital, Dongying, 257000, China.
Microb Pathog. 2025 Aug;205:107524. doi: 10.1016/j.micpath.2025.107524. Epub 2025 Apr 9.
Pediatric pneumonia is a leading life-threatening condition affecting children worldwide, particularly those under the age of five, and is primarily caused by Streptococcus pneumoniae. The virulence factors of streptococcal species pose significant challenges to managing child health, often rendering current antibiotic treatments ineffective. This research highlights the anti-virulence potential of catechin and cyclodextrin combined with PLGA polymer against strains of S. pneumoniae and MRSA, with minimum inhibitory concentrations of 130 μg/mL and 128 μg/mL. The CA/CD@PLGA nanoparticles have demonstrated the ability to prevent these infectious pathogens from developing antibiotic resistance. Results from antibiofilm activity studies suggest that incorporating phytocompounds and polymers enhances the sustained release of targeted molecules onto bacterial cells, achieving an 83 % reduction in biofilm formation. Growth inhibition studies confirm that the CA/CD@PLGA nanospheres effectively suppress bacterial multiplication through a mechanism involving reactive oxygen species (ROS)-mediated cytotoxicity. The agar well diffusion assay concluded that CA/CD@PLGA significantly enhanced the release of catechin and cyclodextrin against both S. pneumoniae and MRSA. Furthermore, antifungal activity tests revealed that the interaction between catechin and cyclodextrin disrupts protein synthesis mechanisms in fungi such as Aspergillus fumigatus and Candida albicans. In vitro cytotoxicity results showed that 93 % of cells remained healthy, confirming that CA/CD@PLGA nanospheres are non-toxic to fibroblast cells. Overall, this research indicates that CA/CD@PLGA nanospheres could be an effective therapeutic option for controlling pediatric pneumonia. Looking ahead, this approach has the potential to become a promising and low-cost therapy for pneumonia management in nursing care applications.
小儿肺炎是一种威胁全球儿童生命的主要疾病，尤其是五岁以下的儿童，主要由肺炎链球菌引起。链球菌属的毒力因子给儿童健康管理带来了重大挑战，常常使目前的抗生素治疗无效。本研究强调了儿茶素和环糊精与聚乳酸-羟基乙酸共聚物（PLGA）结合对肺炎链球菌和耐甲氧西林金黄色葡萄球菌（MRSA）菌株的抗毒力潜力，其最低抑菌浓度分别为130μg/mL和128μg/mL。CA/CD@PLGA纳米颗粒已证明有能力防止这些传染性病原体产生抗生素耐药性。抗生物膜活性研究结果表明，加入植物化合物和聚合物可增强靶向分子在细菌细胞上的持续释放，使生物膜形成减少83%。生长抑制研究证实，CA/CD@PLGA纳米球通过一种涉及活性氧（ROS）介导的细胞毒性机制有效抑制细菌繁殖。琼脂孔扩散试验得出结论，CA/CD@PLGA能显著增强儿茶素和环糊精对肺炎链球菌和MRSA的释放。此外，抗真菌活性测试表明，儿茶素和环糊精之间的相互作用会破坏烟曲霉和白色念珠菌等真菌中的蛋白质合成机制。体外细胞毒性结果显示，93%的细胞保持健康，证实CA/CD@PLGA纳米球对成纤维细胞无毒。总体而言，本研究表明CA/CD@PLGA纳米球可能是控制小儿肺炎的一种有效治疗选择。展望未来，这种方法有可能成为护理应用中治疗肺炎的一种有前景且低成本的疗法。
